News | August 02, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
Strong topline growth driven by solid performance across key brands.
Strong topline growth driven by solid performance across key brands.
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
